5ZV2
| FGFR-1 in complex with ligand lenvatinib | Descriptor: | 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide, Fibroblast growth factor receptor 1 | Authors: | Matsuki, M, Hoshi, T, Yamamoto, Y, Ikemori-Kawada, M, Minoshima, Y, Funahashi, Y, Matsui, J. | Deposit date: | 2018-05-09 | Release date: | 2018-07-11 | Last modified: | 2023-11-22 | Method: | X-RAY DIFFRACTION (2.86 Å) | Cite: | Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med, 7, 2018
|
|
8YKI
| FGFR-1 in complex with ligand tasurgratinib | Descriptor: | CHLORIDE ION, Fibroblast growth factor receptor 1, Tasurgratinib | Authors: | Ikemori-Kawada, M, Watanabe Miyano, S. | Deposit date: | 2024-03-05 | Release date: | 2024-06-12 | Method: | X-RAY DIFFRACTION (2.79 Å) | Cite: | Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion. Anticancer Res., 44, 2024
|
|
3WZE
| KDR in complex with ligand sorafenib | Descriptor: | 2,3-DIHYDROXY-1,4-DITHIOBUTANE, 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE, ACETATE ION, ... | Authors: | Okamoto, K, Ikemori_Kawada, M, Inoue, A, Matsui, J. | Deposit date: | 2014-09-24 | Release date: | 2015-05-27 | Method: | X-RAY DIFFRACTION (1.9 Å) | Cite: | Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. ACS MED.CHEM.LETT., 6, 2015
|
|
3WZD
| KDR in complex with ligand lenvatinib | Descriptor: | 1,2-ETHANEDIOL, 2,3-DIHYDROXY-1,4-DITHIOBUTANE, 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide, ... | Authors: | Okamoto, K, Ikemori_Kawada, M, Inoue, A, Matsui, J. | Deposit date: | 2014-09-24 | Release date: | 2015-05-27 | Method: | X-RAY DIFFRACTION (1.57 Å) | Cite: | Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. ACS MED.CHEM.LETT., 6, 2015
|
|